AC Immune SA Shares Outstanding 2016-2021 | ACIU

AC Immune SA shares outstanding from 2016 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
AC Immune SA Annual Shares Outstanding
(Millions of Shares)
2020 72
2019 71
2018 62
2017 57
2016 50
2015 46
AC Immune SA Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 73
2021-03-31 72
2020-12-31 72
2020-09-30 72
2020-06-30 72
2020-03-31 72
2019-12-31 71
2019-09-30 72
2019-06-30 70
2019-03-31 71
2018-12-31 62
2018-09-30 65
2018-06-30 57
2018-03-31 57
2017-12-31 57
2017-09-30 57
2017-06-30 57
2017-03-31 57
2016-09-30 51
2016-06-30
2016-03-31 46
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.519B $0.016B
AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29